<DOC>
	<DOCNO>NCT01066169</DOCNO>
	<brief_summary>As recommend Dutch Health Council , certain risk group health care worker The Netherlands vaccinate prevent morbidity due pandemic influenza A/H1N1 . Adults vaccinate twice monovalent influenza A/California/2009 ( H1N1 ) MF59-adjuvanted surface-antigen vaccine Focetria® ( Novartis ) . The vaccination campaign execute general practitioner . The aim study verify whether HIV-infected individual generate adequate immune response first second vaccination .</brief_summary>
	<brief_title>Vaccination Response ImmunoCompromised Host . Immune Response After Vaccination Against Pandemic A/H1N1 Influenza</brief_title>
	<detailed_description>AIM OF THIS STUDY : Primary objective : Do HIV-infected individual mount protective humoral response follow vaccination pandemic influenza A/H1N1 monovalent influenza A/California/2009 ( H1N1 ) MF59-adjuvanted surface-antigen vaccine Focetria® ( Novartis ) . Secondary objective : 1 ) To evaluate strength immune response HIV-infected individual compare healthy volunteer . 2 ) To evaluate whether second dose , administer least 21 day first increase proportion HIV-infected individual titer threshold associate protection . 3 ) To assess whether vaccination associate increase HIV-replication . 4 ) To assess whether early antibody response occur , may may indicate immunological memory , example due cross reactivity past influenza infection vaccination . STUDY DESIGN : This interventional study . In single-centre observational study monitor immune response cohort people vaccinate national vaccination campaign . Population : The population base study consist HIV-infected adult outpatient hospital healthy hospital employee . All Dutch English speak HIV-infected LUMC outpatients 18 year age , stable antiretroviral regimen yet need treatment , send letter invite take part . Healthy hospital employee invite take part letter , hand upon vaccination . Inclusion possible three day first vaccination . Exclusion criterion : use systemic immunosuppressive medication , ongoing infection , recent flu-like symptom pregnancy . The following characteristic document baseline : age , gender , co-morbidity , medication , year prior influenza vaccination year diagnosis HIV infection . All participant request fill standardize diary assess flu-like symptom use new medication 60 day follow-up . Laboratory analysis : Lymphocyte count determine baseline , prior vaccination . A serum sample take prior first vaccination ( day -30 day 0 ) , prior second vaccination ( day 17-20 ) second vaccination ( day 60 ) . Viral load determine baseline ( day -30 day 0 ) second vaccination ( day 5-7 ) subgroup 10 person undetectable viral load precede outpatient visit . Antibody response detect duplicate sample mean hemagglutination-inhibition ( HI ) assay accord standard method Erasmus Medical Center Rotterdam . Statistical analysis : No formal sample-size calculation perform . We intend include maximum 100 subject HIV 50 healthy hospital employee . The crude outcome estimate adjust variable may influence outcome ( age , CD4 lymphocyte count , use HAART , viral load ) .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Above 18 year age Stable antiretroviral regimen yet need treatment ( case HIVinfected patient ) Use systemic immunosuppressive medication An ongoing infection Recent flulike symptom pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Pandemic Influenza A/H1N1</keyword>
	<keyword>HIV</keyword>
	<keyword>Antibodies</keyword>
	<keyword>Replicaton</keyword>
</DOC>